Search Within

David Henry Aggen

Formats
  1. Meeting Abstract (45)
  2. Journal Article (10)
  3. Editorial (2)
  4. Research Letter (2)
  5. Review (1)
Groups
  1. Department of Medicine (60)
  2. Genitourinary Oncology Service (60)
  3. Hematologic Malignancies, Division of (60)
  4. Solid Tumor Oncology Division (60)
  5. Weinberg Fellows (42)
  6. Graduate Medical Education (38)

More Groups

People
  1. Jonathan Rosenberg (31)
  2. Gopakumar Iyer (29)
  3. Dean Bajorin (26)
  4. Samuel Funt (26)
  5. Min Yuen Teo (25)
  6. Chung-Han Lee (22)

More People

Years
  1. 2025 (9)
  2. 2024 (17)
  3. 2023 (12)
  4. 2022 (10)
  5. 2021 (7)
  6. 2020 (4)

More Years

Publications
  1. Journal of Clinical Oncology (37)
  2. Clinical Cancer Research (4)
  3. Cancer Research (3)
  4. European Urology (3)
  5. Journal for ImmunoTherapy of Cancer (3)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (38)
  2. American Association for Cancer Research (7)
  3. Biomed Central Ltd (3)
  4. Elsevier Science, Inc. (3)
  5. Elsevier Inc. (2)
  6. Nature Publishing Group (2)

More Publishers

Results (60)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term outcomes of adrenal insufficiency (AI) due to anti-PD(L)-1 immune checkpoint inhibitors (ICI) among patients with cancer
    Meeting Abstract

    Nguyen, B.; Shah, N. J.; Knezevic, A.; Newman, S.; Fitzgerald, K. N.; Kotecha, R.; Lee, C. H.; Carlo, M. I.; Aggen, D. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma
    Meeting Abstract

    McKean, M.; Aggen, D. H.; Lakhani, N. J.; Bashir, B.; Luke, J. J.; Hoffman-Censits, J. H.; Alhalabi, O.; Bowman, I. A.; Guancial, E. A.; Tan, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Biomarkers of response to neoadjuvant atezolizumab with gemcitabine and cisplatin in muscle-invasive bladder cancer
    Meeting Abstract

    Lattanzi, M.; Solovyov, A.; Lihm, J.; Quinlan, C.; Whiting, K.; Li, H.; Al-Ahmadie, H. A.; Teo, M. Y.; Aggen, D. H.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates
    Journal Article

    Lee, C. H.; Voss, M. H.; Carlo, M. I.; Chen, Y. B.; Zucker, M.; Knezevic, A.; Lefkowitz, R. A.; Shapnik, N.; Dadoun, C.; Reznik, E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Favorable toxicity of chemoradiation for muscle-invasive bladder cancer in elderly, frail patients
    Meeting Abstract

    Moore, A.; Zhang, Z.; Bochner, B. H.; Donahue, T. F.; Rosenberg, J. E.; Iyer, G.; Funt, S. A.; Bajorin, D. F.; Teo, M. Y.; Aggen, D. H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Incidence and clinical outcomes of HER2-altered bladder cancer (BC) patients (pts)
    Meeting Abstract

    Lattanzi, M.; Niederhausern, A.; Zheng, J.; Bahadur, N.; Nichols, C.; Barton, L.; Gandhi, F.; Chan, K.; Insinga, A.; Philip, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: A multicenter, single-arm, phase II trial
    Journal Article

    Funt, S. A.; Lattanzi, M.; Whiting, K.; Al-Ahmadie, H.; Quinlan, C.; Teo, M. Y.; Lee, C. H.; Aggen, D.; Zimmerman, D.; McHugh, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1a/b study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally dvanced or metastatic solid tumors and urothelial carcinoma
    Meeting Abstract

    McKean, M.; Luke, J.; Lakhani, N.; Bashir, B.; Aggen, D.; Tan, A.; Kacena, K.; Wang, L.; Timothy, M.; Santillana, S.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Voss, M. H.; Carlo, M. I.; Chen, Y. B.; Reznik, E.; Knezevic, A.; Lefkowitz, R. A.; Shapnik, N.; Tassone, D.; Dadoun, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save